
<!DOCTYPE html>
<html>
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta http-equiv="X-UA-Compatible" content="ie=edge">
<title>Markmap</title>
<style>
* {
  margin: 0;
  padding: 0;
}
#mindmap {
  display: block;
  width: 100vw;
  height: 100vh;
}
</style>
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/markmap-toolbar@0.17.0/dist/style.css">
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/katex@0.16.8/dist/katex.min.css">
</head>
<body>
<svg id="mindmap"></svg>
<script src="https://cdn.jsdelivr.net/npm/d3@7.8.5/dist/d3.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/markmap-view@0.17.0/dist/browser/index.js"></script>
<script src="https://cdn.jsdelivr.net/npm/markmap-toolbar@0.17.0/dist/index.js"></script>
<script>
window.WebFontConfig = {
  custom: {
    families: [
      "KaTeX_AMS","KaTeX_Caligraphic:n4,n7","KaTeX_Fraktur:n4,n7",
      "KaTeX_Main:n4,n7,i4,i7","KaTeX_Math:i4,i7","KaTeX_Script",
      "KaTeX_SansSerif:n4,n7,i4","KaTeX_Size1","KaTeX_Size2",
      "KaTeX_Size3","KaTeX_Size4","KaTeX_Typewriter"
    ],
    active: function() {
      window.markmap.refreshHook.call();
    }
  }
};
</script>
<script src="https://cdn.jsdelivr.net/npm/webfontloader@1.6.28/webfontloader.js" defer></script>
<script>
(() => {
  setTimeout(() => {
    const { markmap: Markmap, mm: markmapInstance } = window;
    const toolbar = new Markmap.Toolbar();
    toolbar.attach(markmapInstance);
    const toolbarElement = toolbar.render();
    toolbarElement.style.position = 'absolute';
    toolbarElement.style.bottom = '20px';
    toolbarElement.style.right = '20px';
    document.body.append(toolbarElement);
  });

  ((getMarkmap, getOptions, root, jsonOptions) => {
    const markmap = getMarkmap();
    window.mm = markmap.Markmap.create(
      "svg#mindmap",
      (getOptions || markmap.deriveOptions)(jsonOptions),
      root
    );
  })(() => window.markmap, null, {"content":"BCM Breast Cancer Trials","children":[{"content":"MED ONC","children":[{"content":"Adjuvant","children":[{"content":"HER2","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"4,5\"><strong>FLAMINGO -01</strong></p>","children":[{"content":"\n<p data-lines=\"6,7\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Stage I/II with nonpCR OR stage III (pCR or not) to be enorlled &lt;90 days from completion of HP/TDM1</p>","children":[],"payload":{"lines":"6,9"}},{"content":"\n<p data-lines=\"9,10\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TWO cohorst depending on HLA-A-02</p>","children":[],"payload":{"lines":"9,10"}}],"payload":{"lines":"4,10"}},{"content":"\n<p data-lines=\"10,11\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"12,13\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"12,15"}},{"content":"\n<p data-lines=\"15,16\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"15,16"}}],"payload":{"lines":"10,16"}},{"content":"\n<p data-lines=\"16,17\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"18,19"}}],"payload":{"lines":"16,19"}},{"content":"\n<p data-lines=\"19,20\">ADEPT</p>","children":[{"content":"\n<p data-lines=\"21,22\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ OR PR+ with HER2+ disease T1A/B/C. N1mi allowed.</p>","children":[],"payload":{"lines":"21,24"}},{"content":"\n<p data-lines=\"24,25\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No more than 8 weeks of ET</p>","children":[],"payload":{"lines":"24,25"}}],"payload":{"lines":"19,25"}}],"payload":{"lines":"3,25"}}],"payload":{"lines":"2,25"}},{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"27,28\"><strong>CAMBRIA-1</strong></p>","children":[{"content":"\n<p data-lines=\"29,30\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Intermediate and High risk to randomize between adjuvant year 2 : 5 to either continue adj. ET SoC vs oral SERD</p>","children":[],"payload":{"lines":"29,32"}},{"content":"\n<p data-lines=\"32,33\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Intermediate: T3 N0 | T1c/T2 N1 [2-3 LN] | T1c/T2 N0 (Grade III, KI67 &gt;= 20%, LumB/RS26, or prior chemotherapy)</p>","children":[],"payload":{"lines":"32,35"}},{"content":"\n<p data-lines=\"35,36\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> High: Stage III | T1c/T2 N1 [2-3]  (Grade III, KI67 &gt;= 20%, LumB/RS26) | T1c/T2 N1 [1/3] (Grade III, KI67 &gt;= 20%, LumB/RS26)</p>","children":[],"payload":{"lines":"35,36"}}],"payload":{"lines":"27,36"}},{"content":"\n<p data-lines=\"36,37\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"38,39\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"38,41"}},{"content":"\n<p data-lines=\"41,42\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"41,42"}}],"payload":{"lines":"36,42"}},{"content":"\n<p data-lines=\"42,43\"><strong>OFSET (NRG BR009)</strong></p>","children":[{"content":"\n<p data-lines=\"44,45\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ (&gt;1%) HER2- with pT1-3 pN0-1.</p>","children":[],"payload":{"lines":"44,47"}},{"content":"\n<p data-lines=\"47,48\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> RS N1 &lt;26. RS N0 21-25. RS N0 16-20 WITH T minimum at 30mm (G1), 20mm (G2) or 10mm (G3)</p>","children":[],"payload":{"lines":"47,48"}}],"payload":{"lines":"42,48"}},{"content":"\n<p data-lines=\"48,49\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"50,51"}}],"payload":{"lines":"48,51"}},{"content":"\n<p data-lines=\"51,52\">ELEGANT</p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ High Risk (Defined by trial) between year 2 and 5 of adjuvant ET +/- CDK4/6i or PARPi","children":[],"payload":{"lines":"53,54"}}],"payload":{"lines":"51,54"}},{"content":"\n<p data-lines=\"54,55\"><strong>LoTAM</strong></p>","children":[{"content":"\n<p data-lines=\"56,57\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Stage 1 and 2A (T &lt; 30mm, N0) ER+ (&gt;10%) HER2- Breast Cancer</p>","children":[],"payload":{"lines":"56,59"}},{"content":"\n<p data-lines=\"59,60\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> LOW Genomic risk (MP LOW, RS &lt;26 OR ProSigna &lt;40)</p>","children":[],"payload":{"lines":"59,60"}}],"payload":{"lines":"54,60"}}],"payload":{"lines":"26,60"}}],"payload":{"lines":"25,60"}},{"content":"TNBC","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"62,63\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"64,65\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"64,67"}},{"content":"\n<p data-lines=\"67,68\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"67,68"}}],"payload":{"lines":"62,68"}},{"content":"\n<p data-lines=\"68,69\"><strong>OptimICE-PCR</strong></p>","children":[{"content":"\n<p data-lines=\"70,71\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC (ER/PR &lt;10%)  T1cN1-2 or T2-4N0-2 with ypT0 OR ypTis</p>","children":[],"payload":{"lines":"70,73"}},{"content":"\n<p data-lines=\"73,74\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adju RT  and Pembro, followed by registration</p>","children":[],"payload":{"lines":"73,74"}}],"payload":{"lines":"68,74"}},{"content":"\n<p data-lines=\"74,75\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"76,77"}}],"payload":{"lines":"74,77"}}],"payload":{"lines":"61,77"}}],"payload":{"lines":"60,77"}}],"payload":{"lines":"1,77"}},{"content":"Metastatic","children":[{"content":"HER2","children":[{"content":"2","children":[{"content":"\n<p data-lines=\"80,81\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"82,83\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"82,85"}},{"content":"\n<p data-lines=\"85,86\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"85,86"}}],"payload":{"lines":"80,86"}}],"payload":{"lines":"79,86"}},{"content":"3","children":[{"content":"\n<p data-lines=\"87,88\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"89,90\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"89,92"}},{"content":"\n<p data-lines=\"92,93\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"92,93"}}],"payload":{"lines":"87,93"}}],"payload":{"lines":"86,93"}},{"content":"4","children":[{"content":"\n<p data-lines=\"94,95\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"96,97\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"96,99"}},{"content":"\n<p data-lines=\"99,100\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"99,100"}}],"payload":{"lines":"94,100"}}],"payload":{"lines":"93,100"}}],"payload":{"lines":"78,100"}},{"content":"HR POS","children":[{"content":"1","children":[{"content":"\n<p data-lines=\"102,103\"><strong>EvoPAR-Breast01</strong></p>","children":[{"content":"\n<p data-lines=\"104,105\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> DenoVo metastatic opr 1ry resistant ER+ (&gt;1%)</p>","children":[],"payload":{"lines":"104,107"}},{"content":"\n<p data-lines=\"107,108\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> BRCA1/2 OR PALB2 (either germline or somatic)</p>","children":[],"payload":{"lines":"107,108"}}],"payload":{"lines":"102,108"}}],"payload":{"lines":"101,108"}},{"content":"2","children":[{"content":"\n<p data-lines=\"109,110\"><strong>ELAINE-III</strong></p>","children":[{"content":"\n<p data-lines=\"111,112\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Progression on 1st Line CDK4/6. ESR1 mutation</p>","children":[],"payload":{"lines":"111,114"}},{"content":"\n<p data-lines=\"114,115\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No priot Abema in adjuvant or metastatic setting</p>","children":[],"payload":{"lines":"114,115"}}],"payload":{"lines":"109,115"}},{"content":"\n<p data-lines=\"115,116\"><strong>OPERA-1</strong></p>","children":[{"content":"\n<p data-lines=\"117,118\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Post 1st Line progression while on ET/CDK , adjuvant ET or within 2 years post ET. No prior Chemo in Stage 4.</p>","children":[],"payload":{"lines":"117,120"}},{"content":"\n<p data-lines=\"120,121\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Part A three arm for OP 120, OP 90 and SoC. Part B is OP vs SoC [Faslo or AI]</p>","children":[],"payload":{"lines":"120,121"}}],"payload":{"lines":"115,121"}},{"content":"\n<p data-lines=\"121,122\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"123,124\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"123,126"}},{"content":"\n<p data-lines=\"126,127\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"126,127"}}],"payload":{"lines":"121,127"}},{"content":"\n<p data-lines=\"127,128\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"129,130\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"129,132"}},{"content":"\n<p data-lines=\"132,133\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ HER2- must have progressed on or within 12 months of adjuvant ET, OR got minimum of 1L of ET (including prior CDK4/6)</p>","children":[],"payload":{"lines":"132,133"}}],"payload":{"lines":"127,133"}},{"content":"\n<p data-lines=\"133,134\">QuantifyHER</p>","children":[{"content":"\n<p data-lines=\"135,136\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ IHC 1+ who will start Enhertu (Or within 30 days after starting)</p>","children":[],"payload":{"lines":"135,138"}},{"content":"\n<p data-lines=\"138,139\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible</p>","children":[],"payload":{"lines":"138,139"}}],"payload":{"lines":"133,139"}}],"payload":{"lines":"108,139"}},{"content":"3","children":[{"content":"\n<p data-lines=\"140,141\"><strong>OPERA-1</strong></p>","children":[{"content":"\n<p data-lines=\"142,143\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Post 2 Lines Line of ET, lasting at least 6 months. No prior Chemo in Stage 4.</p>","children":[],"payload":{"lines":"142,145"}},{"content":"\n<p data-lines=\"145,146\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Part A three arm for OP 120, OP 90 and SoC. Part B is OP vs SoC [Faslo or AI]</p>","children":[],"payload":{"lines":"145,148"}},{"content":"\n<p data-lines=\"148,149\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If 2nd line was Faslo, 3rd line SoC can be AI</p>","children":[],"payload":{"lines":"148,149"}}],"payload":{"lines":"140,149"}},{"content":"\n<p data-lines=\"149,150\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"151,152\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"151,154"}},{"content":"\n<p data-lines=\"154,155\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"154,155"}}],"payload":{"lines":"149,155"}},{"content":"\n<p data-lines=\"155,156\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"157,158\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"157,160"}},{"content":"\n<p data-lines=\"160,161\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Received 1st Line ET (including CDK4/6i), 2nd Line,</p>","children":[],"payload":{"lines":"160,161"}}],"payload":{"lines":"155,161"}},{"content":"\n<p data-lines=\"161,162\">QuantifyHER</p>","children":[{"content":"\n<p data-lines=\"163,164\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ IHC 1+ who will start Enhertu (Or within 30 days after starting)</p>","children":[],"payload":{"lines":"163,166"}},{"content":"\n<p data-lines=\"166,167\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible</p>","children":[],"payload":{"lines":"166,167"}}],"payload":{"lines":"161,167"}}],"payload":{"lines":"139,167"}},{"content":"4","children":[{"content":"\n<p data-lines=\"168,169\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"170,171\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"170,173"}},{"content":"\n<p data-lines=\"173,174\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"173,174"}}],"payload":{"lines":"168,174"}},{"content":"\n<p data-lines=\"174,175\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"176,177\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"176,179"}},{"content":"\n<p data-lines=\"179,180\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Received 1st Line ET (including CDK4/6i), 2nd Line, and on 3rd Line ADC. Can join directly to ADC2 at 4th L from Dato or Enhertu</p>","children":[],"payload":{"lines":"179,180"}}],"payload":{"lines":"174,180"}},{"content":"\n<p data-lines=\"180,181\">QuantifyHER</p>","children":[{"content":"\n<p data-lines=\"182,183\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ IHC 1+ who will start Enhertu (Or within 30 days after starting)</p>","children":[],"payload":{"lines":"182,185"}},{"content":"\n<p data-lines=\"185,186\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible</p>","children":[],"payload":{"lines":"185,186"}}],"payload":{"lines":"180,186"}}],"payload":{"lines":"167,186"}}],"payload":{"lines":"100,186"}},{"content":"TNBC","children":[{"content":"1","children":[{"content":"\n<p data-lines=\"188,189\"><strong>TBCRC 061</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Receipt of Immunotherapy in the advanced setting","children":[],"payload":{"lines":"190,191"}}],"payload":{"lines":"188,191"}},{"content":"\n<p data-lines=\"191,192\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"193,194\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0+/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"193,196"}},{"content":"\n<p data-lines=\"196,197\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC Strict 0-1 prior lines.</p>","children":[],"payload":{"lines":"196,197"}}],"payload":{"lines":"191,197"}}],"payload":{"lines":"187,197"}},{"content":"2","children":[{"content":"\n<p data-lines=\"198,199\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"200,201\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"200,203"}},{"content":"\n<p data-lines=\"203,204\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"203,204"}}],"payload":{"lines":"198,204"}},{"content":"\n<p data-lines=\"204,205\"><strong>TBCRC 061</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Receipt of Immunotherapy in the advanced setting","children":[],"payload":{"lines":"206,207"}}],"payload":{"lines":"204,207"}},{"content":"\n<p data-lines=\"207,208\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"209,210\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0+/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"209,212"}},{"content":"\n<p data-lines=\"212,213\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC Strict 0-1 prior lines, but can join from Enhertu 2L to Dato</p>","children":[],"payload":{"lines":"212,213"}}],"payload":{"lines":"207,213"}},{"content":"\n<p data-lines=\"213,214\">QuantifyHER</p>","children":[{"content":"\n<p data-lines=\"215,216\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER- IHC 1+ who will start Enhertu (Or within 30 days after starting)</p>","children":[],"payload":{"lines":"215,218"}},{"content":"\n<p data-lines=\"218,219\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible\"</p>","children":[],"payload":{"lines":"218,219"}}],"payload":{"lines":"213,219"}}],"payload":{"lines":"197,219"}},{"content":"3","children":[{"content":"\n<p data-lines=\"220,221\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"222,223\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"222,225"}},{"content":"\n<p data-lines=\"225,226\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"225,226"}}],"payload":{"lines":"220,226"}},{"content":"\n<p data-lines=\"226,227\"><strong>TBCRC 061</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Receipt of Immunotherapy in the advanced setting","children":[],"payload":{"lines":"228,229"}}],"payload":{"lines":"226,229"}},{"content":"\n<p data-lines=\"229,230\"><strong>TBCRC 064</strong></p>","children":[{"content":"\n<p data-lines=\"231,232\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> IHC 0+/1/2 with NEG FISH. Research Bx at baseline ADC1, 3Wk ADC1, Baseline ADC and progression ADC2</p>","children":[],"payload":{"lines":"231,234"}},{"content":"\n<p data-lines=\"234,235\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC Strict 0-1 prior lines, but can join from Enhertu 2L to Dato</p>","children":[],"payload":{"lines":"234,235"}}],"payload":{"lines":"229,235"}},{"content":"\n<p data-lines=\"235,236\">QuantifyHER</p>","children":[{"content":"\n<p data-lines=\"237,238\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER- IHC 1+ who will start Enhertu (Or within 30 days after starting)</p>","children":[],"payload":{"lines":"237,240"}},{"content":"\n<p data-lines=\"240,241\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Tissue from IHC1+ samples must be sent. Decalcified bone tissue ineligible\"</p>","children":[],"payload":{"lines":"240,241"}}],"payload":{"lines":"235,241"}}],"payload":{"lines":"219,241"}},{"content":"4","children":[{"content":"\n<p data-lines=\"242,243\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"244,245\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"244,247"}},{"content":"\n<p data-lines=\"247,248\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"247,248"}}],"payload":{"lines":"242,248"}}],"payload":{"lines":"241,248"}}],"payload":{"lines":"186,248"}}],"payload":{"lines":"77,248"}},{"content":"Neoadjuvant","children":[{"content":"HER2","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"251,252\"><strong>RESPONSE</strong></p>","children":[{"content":"\n<p data-lines=\"253,254\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers</p>","children":[],"payload":{"lines":"253,256"}},{"content":"\n<p data-lines=\"256,257\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Will receive weekly Taxol HP  with ddAC</p>","children":[],"payload":{"lines":"256,257"}}],"payload":{"lines":"251,257"}},{"content":"\n<p data-lines=\"257,258\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"259,260\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"259,262"}},{"content":"\n<p data-lines=\"262,263\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"262,263"}}],"payload":{"lines":"257,263"}},{"content":"\n<p data-lines=\"263,264\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"265,266"}}],"payload":{"lines":"263,266"}}],"payload":{"lines":"250,266"}}],"payload":{"lines":"249,266"}},{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"268,269\"><strong>RESPONSE</strong></p>","children":[{"content":"\n<p data-lines=\"270,271\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers</p>","children":[],"payload":{"lines":"270,273"}},{"content":"\n<p data-lines=\"273,274\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> High Risk ER+ (Grade III, Age &lt;50, ER &lt; 6/8 OR Ki67 &gt;29%). Will receive weekly Taxol with ddAC</p>","children":[],"payload":{"lines":"273,274"}}],"payload":{"lines":"268,274"}},{"content":"\n<p data-lines=\"274,275\"><strong>EVANGELINE</strong></p>","children":[{"content":"\n<p data-lines=\"276,277\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Clinical T2 or T3 and N0 or N1 with Grade I and II</p>","children":[],"payload":{"lines":"276,279"}},{"content":"\n<p data-lines=\"279,280\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ 67% or more, Allred 6-8</p>","children":[],"payload":{"lines":"279,280"}}],"payload":{"lines":"274,280"}},{"content":"\n<p data-lines=\"280,281\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"282,283\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"282,285"}},{"content":"\n<p data-lines=\"285,286\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"285,286"}}],"payload":{"lines":"280,286"}},{"content":"\n<p data-lines=\"286,287\">NCBRE</p>","children":[{"content":"\n<p data-lines=\"288,289\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ILC ER+ PR+ HER2- with ERBB2 mutation.</p>","children":[],"payload":{"lines":"288,291"}},{"content":"\n<p data-lines=\"291,292\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1c (Min size 15mm) N0/N1/N2</p>","children":[],"payload":{"lines":"291,292"}}],"payload":{"lines":"286,292"}},{"content":"\n<p data-lines=\"292,293\"><strong>S2206</strong></p>","children":[{"content":"\n<p data-lines=\"294,295\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Stage II and III, including IBC. ER+ or PR+ per CAP (&gt;1%)</p>","children":[],"payload":{"lines":"294,297"}},{"content":"\n<p data-lines=\"297,298\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> High 2 on MP</p>","children":[],"payload":{"lines":"297,298"}}],"payload":{"lines":"292,298"}},{"content":"\n<p data-lines=\"298,299\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"300,301"}}],"payload":{"lines":"298,301"}}],"payload":{"lines":"267,301"}}],"payload":{"lines":"266,301"}},{"content":"TNBC","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"303,304\"><strong>RESPONSE</strong></p>","children":[{"content":"\n<p data-lines=\"305,306\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers</p>","children":[],"payload":{"lines":"305,308"}},{"content":"\n<p data-lines=\"308,309\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Will receive weekly Taxol with ddAC (Pembro added if indicated, Carbo added if T3)</p>","children":[],"payload":{"lines":"308,309"}}],"payload":{"lines":"303,309"}},{"content":"\n<p data-lines=\"309,310\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"311,312\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"311,314"}},{"content":"\n<p data-lines=\"314,315\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"314,315"}}],"payload":{"lines":"309,315"}},{"content":"\n<p data-lines=\"315,316\"><strong>S2212</strong></p>","children":[{"content":"\n<p data-lines=\"317,318\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC (ER/PR &lt;5%) with T2-T4 N0 OR T1-T3 N1-N2. Randomized to either KN522 versus Taxotere Carbo  Pembro x 6 Cycles</p>","children":[],"payload":{"lines":"317,320"}},{"content":"\n<p data-lines=\"320,321\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No Stage IIIC, IIIB T4 N+ OR IBC</p>","children":[],"payload":{"lines":"320,321"}}],"payload":{"lines":"315,321"}},{"content":"\n<p data-lines=\"321,322\"><strong>FLEX</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"323,324"}}],"payload":{"lines":"321,324"}},{"content":"\n<p data-lines=\"324,325\"><strong>TNBC ctDNA Tissue Banking</strong></p>","children":[{"content":"\n<p data-lines=\"326,327\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC Stage II/III receiving NACT (+/- ICB)</p>","children":[],"payload":{"lines":"326,329"}},{"content":"\n<p data-lines=\"329,330\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ctDNA collected after Taxol and after AC, both before definitive surgery</p>","children":[],"payload":{"lines":"329,330"}}],"payload":{"lines":"324,330"}}],"payload":{"lines":"302,330"}}],"payload":{"lines":"301,330"}}],"payload":{"lines":"248,330"}}],"payload":{"lines":"0,330"}},{"content":"RAD ONC","children":[{"content":"Adjuvant","children":[{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"334,335\"><strong>MA39</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Newly Diagnosis of IDC w/ no metastisis<br>\nTreated with BCS or Mastectomy with no residual disease","children":[],"payload":{"lines":"336,338"}}],"payload":{"lines":"334,338"}}],"payload":{"lines":"333,338"}}],"payload":{"lines":"332,338"}}],"payload":{"lines":"331,338"}},{"content":"Postsurgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"341,342\">PREDICT II</p>","children":[{"content":"\n<p data-lines=\"343,344\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dx of DCIS w/ tumor size &lt;6cm</p>","children":[],"payload":{"lines":"343,346"}},{"content":"\n<p data-lines=\"346,347\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Eligible for BCS, radiation and/or systemic treatment</p>","children":[],"payload":{"lines":"346,347"}}],"payload":{"lines":"341,347"}}],"payload":{"lines":"340,347"}}],"payload":{"lines":"339,347"}}],"payload":{"lines":"338,347"}}],"payload":{"lines":"330,347"}},{"content":"SURG ONC","children":[{"content":"Peri-Surgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"351,352\"><strong>CHEST</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Undergoing Mastectomy + Reconstruction","children":[],"payload":{"lines":"353,354"}}],"payload":{"lines":"351,354"}},{"content":"\n<p data-lines=\"354,355\"><strong>Breast ATLAS</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Undergoing PPX Mastectomy","children":[],"payload":{"lines":"356,357"}}],"payload":{"lines":"354,357"}},{"content":"\n<p data-lines=\"357,358\"><strong>PRECISION</strong></p>","children":[{"content":"\n<p data-lines=\"359,360\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dx of DCIS and/or IDC undergoing BCS or mastectomy</p>","children":[],"payload":{"lines":"359,362"}},{"content":"\n<p data-lines=\"362,363\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No hx of prior therapy treatment</p>","children":[],"payload":{"lines":"362,363"}}],"payload":{"lines":"357,363"}},{"content":"\n<p data-lines=\"363,364\"><strong>SentiNot 2.0</strong></p>","children":[{"content":"\n<p data-lines=\"365,366\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Pre-operative diagnosis of DCIS or other suspicious lesion not confirmed to be invasive breast cancer</p>","children":[],"payload":{"lines":"365,368"}},{"content":"\n<p data-lines=\"368,369\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Willing to forgo initial SLNB and have SLNB as a later second procedure if DCIS is upgraded to invasive cancer</p>","children":[],"payload":{"lines":"368,369"}}],"payload":{"lines":"363,369"}},{"content":"\n<p data-lines=\"369,370\"><strong>Magellan</strong></p>","children":[{"content":"\n<p data-lines=\"371,372\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Non-metastatic patients with node positive breast cancer (cT0-4, N1)</p>","children":[],"payload":{"lines":"371,374"}},{"content":"\n<p data-lines=\"374,375\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Magseed placement prior to NAC</p>","children":[],"payload":{"lines":"374,375"}}],"payload":{"lines":"369,375"}}],"payload":{"lines":"350,375"}}],"payload":{"lines":"349,375"}}],"payload":{"lines":"348,375"}},{"content":"Postsurgical","children":[{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"378,379\"><strong>LoTAM</strong></p>","children":[{"content":"\n<p data-lines=\"380,381\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Stage 1 and 2A (T &lt; 30mm, N0) ER+ (&gt;10%) HER2- Breast Cancer</p>","children":[],"payload":{"lines":"380,383"}},{"content":"\n<p data-lines=\"383,384\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> LOW Genomic risk (MP LOW, RS &lt;26 OR ProSigna &lt;40)</p>","children":[],"payload":{"lines":"383,384"}}],"payload":{"lines":"378,384"}}],"payload":{"lines":"377,384"}}],"payload":{"lines":"376,384"}}],"payload":{"lines":"375,384"}},{"content":"Presurgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"387,388\"><strong>ATUSA-iSONO</strong></p>","children":[{"content":"\n<p data-lines=\"389,390\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Women with a suspected breast lesion in one of both breasts</p>","children":[],"payload":{"lines":"389,392"}},{"content":"\n<p data-lines=\"392,393\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Disease T1c or larger</p>","children":[],"payload":{"lines":"392,393"}}],"payload":{"lines":"387,393"}},{"content":"\n<p data-lines=\"393,394\"><strong>BCM TISSUE COLLECTION</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Suspicious lesion receiving an U/S guided biopsy with birads 4b-5","children":[],"payload":{"lines":"395,396"}}],"payload":{"lines":"393,396"}},{"content":"\n<p data-lines=\"396,397\"><strong>ANGEL</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Any suspicious lesion receiving a biopsy","children":[],"payload":{"lines":"398,399"}}],"payload":{"lines":"396,399"}}],"payload":{"lines":"386,399"}}],"payload":{"lines":"385,399"}}],"payload":{"lines":"384,399"}}],"payload":{"lines":"347,399"}}],"payload":{"lines":"0,399"}}, {"initialExpandLevel":4,"maxWidth":250});
})();
</script>
</body>
</html>
